Amifampridine (Firdapse) Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing patients with Lambert-Eaton Myasthenic Syndrome (LEMS), you are already working within a narrow therapeutic landscape. Firdapse (amifampridine) is the only FDA-approved oral therapy for this condition, and helping your patients access it requires navigating a complex web of specialty pharmacy requirements, payer policies, and patient assistance programs. This guide is designed to give you the clinical and operational information you need to expedite access for your LEMS patients in 2026.

Current Supply Status: Not a Traditional Shortage

As of 2026, amifampridine (Firdapse) is not on the FDA's drug shortage database. Catalyst Pharmaceuticals has not reported supply disruptions. However, your patients may still struggle to access this medication due to structural barriers:

Mandatory specialty pharmacy dispensing (retail pharmacies cannot fill this prescription)

Universal prior authorization requirements across all major payers

High specialty tier placement (Tier 4–5) requiring substantial cost-sharing without assistance

Annual reauthorization with documented clinical response required

No generic alternative available (orphan drug exclusivity protects Firdapse)

Prior Authorization: Documentation Requirements by Payer

Prior authorization is required by essentially all commercial insurers, Medicare Part D plans, and Medicaid programs. While exact criteria vary by payer, most require:

Confirmed LEMS diagnosis: Supported by EMG/nerve conduction studies showing >60% CMAP increment on high-frequency stimulation

VGCC antibody results: Positive voltage-gated calcium channel antibodies (present in ~85% of LEMS cases)

Specialist prescribing: Documentation that prescription originates from a neurologist or neuromuscular specialist

Cancer screening: Documentation of malignancy workup, particularly for small-cell lung cancer

Absence of contraindications: No history of seizures; amifampridine is contraindicated in patients with seizure history

Proposed dosing plan: Initial dose and target dose within FDA-approved range (up to 100 mg/day for adults and pediatric patients >45 kg)

Key Clinical Points to Include in PA Documentation

Your medical necessity letter should address four key elements that payers look for:

Confirmed diagnosis with supporting evidence — cite specific EMG findings, VGCC antibody titers, and the name of the specialist center where the workup was performed.

Functional impairment documentation — quantify the patient's weakness using objective measures (Timed 25-Foot Walk Test, dynamometry, QMG score). This helps justify medical necessity.

Clinical guideline support — reference FDA labeling and professional society guidelines that identify amifampridine as first-line therapy for LEMS.

Expected treatment goals — describe specific functional goals and your monitoring plan for assessing clinical response.

When Prior Authorization Is Denied

PA denials for amifampridine are not uncommon, particularly on first submission when documentation is incomplete. The most effective approach upon denial is a peer-to-peer review — a direct conversation between you and the insurer's medical director. Prepare for the peer-to-peer by:

Having the patient's complete EMG/NCS results and VGCC antibody levels ready to cite

Referencing FDA-approved labeling that identifies Firdapse as indicated for LEMS in patients 6 years and older

Describing the lack of approved alternatives (Ruzurgi was withdrawn in 2022; no generic exists)

Providing a clear statement of expected harm if treatment is delayed

39,483+ patients found their medications in stock

39K+

Find Amifampridine In Stock Today →

The 2024 Maximum Dose Update: Update Your PA Submissions

In May 2024, the FDA approved an increase in the maximum approved daily dose of Firdapse from 80 mg to 100 mg for adults and pediatric patients weighing more than 45 kg. If you have patients requiring doses above 80 mg, ensure your PA submissions reference the updated 2024 labeling (NDA 208078). Payers with older policies may need to update their criteria to reflect this change.

Patient Assistance and Bridge Programs

The Catalyst Pathways program (1-833-422-8259) should be initiated for every LEMS patient starting amifampridine. The program offers:

$0 monthly copay for eligible commercially insured patients (program enrollees average <$2/month)

Free bridge medication during the PA process or coverage gap

Specialty pharmacy coordination and PA submission support

NORD RareCare Program referrals for patients with additional financial need (1-800-999-6673)

Skip the calls, skip the stress.

Find Amifampridine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Dosing and Pharmacokinetic Considerations

Amifampridine is extensively metabolized by NAT2 (N-acetyltransferase 2). NAT2 poor metabolizers — who have a prevalence of 40–60% in White and African American populations and 10–30% in Asian populations — have 5.6- to 9-fold higher AUC than fast metabolizers. These patients require particularly careful dose titration. The drug has a short half-life of 1.8–2.5 hours, necessitating 3–5 daily doses to maintain therapeutic effect.

For patients with renal impairment (CrCl 15–90 mL/min), initiate at 15 mg/day in 3 divided doses and monitor closely. Amifampridine has not been studied in patients with end-stage renal disease (CrCl <15 mL/min).

For a practical guide on helping your patients locate amifampridine and navigate pharmacy barriers, visit medfinder for providers or read our provider's guide to helping patients find amifampridine in stock.